江药控股 拟入主太龙药业

Core Viewpoint - Tailong Pharmaceutical (600222) is set to change ownership to Jiangxi State-owned Assets Supervision and Administration Commission, following a week-long suspension of trading, with significant market reactions observed upon resumption of trading [1] Group 1: Ownership Change - Tailong Pharmaceutical's controlling shareholder, Zhengzhou Tairong Industrial Investment Co., Ltd., has signed a share transfer agreement with Jiang Pharmaceutical Group Jiangxi Medical Holdings Co., Ltd. [1] - The agreement involves the transfer of 50.1 million shares, representing 8.73% of the total share capital, at a price of 11.043 yuan per share, which is nearly a 30% premium compared to the price before the suspension [1] - The total transaction value amounts to 553 million yuan [1] Group 2: Shareholding Structure - After the first delivery of 42.3 million shares, Jiang Pharmaceutical Holdings will directly hold 7.37% of the shares and, through a concerted action arrangement, will control a total of 14.37% of the shares [1] - The controlling shareholder will change from Zhengzhou High-tech Industrial Development Zone Management Committee to Jiangxi Provincial State-owned Assets Supervision and Administration Commission [1] Group 3: Corporate Actions - The company's board has approved a plan for a private placement to Jiang Pharmaceutical Holdings [1]